In addition, the JAK2V617F mutation was initially identified from the three driver gene mutations of BCR::ABL1-negative MPNs [3,4,5] and has been most frequently identified among the patients with BCR::ABL1-negative MPNs, and the positivity is approximately 97% in PV and approximately 50% in ET and PMF. This evidence concerns the gene ABL1 and essential thrombocythemia.